Meganest (Articaine Hydrochloride, Epinephrine Bitartrate)

Articaine blocks voltage‑gated sodium channels on nerve membranes, stopping the initiation and propagation of action potentials. This reversible inhibition prevents pain signals from reaching the brain. The added epinephrine constricts local blood vessels, limiting systemic absorption and extending the duration of the anesthetic effect.

The exact dose of Meganet is determined by the prescribing clinician based on the procedure, patient size, and clinical judgment. The product is supplied as a solution for injection, and the prescriber selects the appropriate volume and concentration for each individual case.

Safety data for articaine‑containing products in pregnancy and lactation are limited. Meganet should only be used when the potential benefit justifies any possible risk to the fetus or infant, and this decision must be made by the treating healthcare professional.

To place an order, submit an enquiry on the Meganet product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Meganet contains articaine, which has a higher lipid solubility than lidocaine, allowing faster onset and deeper penetration of soft tissue. The epinephrine component prolongs anesthesia and reduces bleeding. Compared with other amide anesthetics, articaine often provides comparable efficacy with a slightly shorter duration, making it useful for procedures requiring rapid recovery.

Meganet should be stored at temperatures below 25 °C, in its original sealed container, protected from light and moisture. Do not freeze the solution. Before use, inspect the vial for particulate matter or discoloration and discard if any abnormalities are observed.

Meganet is administered by a qualified healthcare professional via infiltration or perineural injection. The solution is drawn into a sterile syringe and injected directly into the target tissue or around the nerve bundle, following aseptic technique and the dosage instructions provided by the prescriber.

Serious risks include allergic reactions such as anaphylaxis, severe cardiovascular events like hypotension or arrhythmias due to epinephrine, methemoglobinemia, prolonged or deep tissue anesthesia, and rare central nervous system toxicity leading to seizures. Immediate medical attention is required if any of these events occur.

Meganet should be avoided in patients with known hypersensitivity to articaine, other amide‑type local anesthetics, or epinephrine. It is also contraindicated in individuals with uncontrolled hypertension, severe cardiac disease, hyperthyroidism, pheochromocytoma, or those taking non‑selective beta‑blockers without careful monitoring.